PTGX
Bearish signalScored 2026-10-27 Drivers: trend, fundamentals. Insiders: neutral. Moteurs : tendance, fondamentaux. Initiés : neutre.
Research, not advice.
À propos
Protagonist Therapeutics, Inc.
- Nom
- Protagonist Therapeutics, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $8.9B
- Employés
- 141
- PDG
- Dinesh V. Patel
- Site web
- https://www.protagonist-inc.com
- Marché
- ACRSANABIMUXIMVTIRONODTX
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 225 000 titres (~33 131 366,81 $ US)
- Insiders
- PATEL DINESH V PH D
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$39,658,067
Avg sell (VWAP, 90d window) $146.32 vs last close $140.32 (-4.1%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$39,658,067 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-09-10
- Liquidity
- Liquid $110,840,087/day · 20d vol
- Last synced
-
2026-10-27 04:43:11
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-30 | Ali Asif | Sell · S · 10b5-1 | 46,034 | $141.78 | $6,526,701 | Form 4 |
| 2026-09-10 | PATEL DINESH V PH D | Sell · S · 10b5-1 | 7,278 | $144.10 | $1,048,760 | Form 4 |
| 2026-09-09 | PATEL DINESH V PH D | Sell · S · 10b5-1 | 63,548 | $146.18 | $9,289,447 | Form 4 |
| 2026-09-08 | PATEL DINESH V PH D | Sell · S · 10b5-1 | 54,174 | $145.87 | $7,902,361 | Form 4 |
| 2026-08-11 | PATEL DINESH V PH D | Sell · S · 10b5-1 | 34,239 | $148.52 | $5,085,176 | Form 4 |
| 2026-08-10 | PATEL DINESH V PH D | Sell · S · 10b5-1 | 65,761 | $149.11 | $9,805,623 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Bearish signalScored 2026-10-27 Drivers: trend, fundamentals. Insiders: neutral. Moteurs : tendance, fondamentaux. Initiés : neutre.
PTGX combines a very weak catalyst score (25) driven by massive CEO insider selling (~$33M) with deteriorating fundamentals — negative EBITDA, 346% R&D-to-sales ratio, and a speculative 120x P/S multiple — that…
The first sentence of the analysis written for PTGX on 2026-10-27 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. – Insider: neutral. All sales (≈ $33.1M) were pre-planned Rule 10b5-1 trades, excluded from the score. No open-market buys or discretionary sales. – Initiés : neutre. Toutes les ventes (≈ $33.1M) sont sous plan 10b5-1 préétabli, exclues du score. Aucun achat ni vente discrétionnaire.
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Unavailable or mixed. Current ratio 12.71 · operating margin -344% — readings disagree
Suggested stop 134.84, nearest stored support minus 0.5 ATR(3.9% under the last close). Reward/risk to the next stored resistance is 0.54. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Recent news
- 2026-10-24 Protagonist Therapeutics: The Opt-Out That Turned A Biotech Into A Royalty Compounder Protagonist Therapeutics has evolved into a royalty-driven company with two FDA-approved drugs, robust liquidity, and a $300 million buyback. PTGX secured lucrative back-end royalties and milestones from Takeda and J&J, shifting risk and execution to partners while retaining substantial economic upside. Consensus forward earnings are nearly 4x trailing levels, underpinned by high-margin royalty streams that could generate $605 million annually against $220 million in expenses.
- 2026-10-19 Analyzing Protagonist Therapeutics (NASDAQ:PTGX) and Sarepta Therapeutics (NASDAQ:SRPT) Protagonist Therapeutics (NASDAQ: PTGX - Get Free Report) and Sarepta Therapeutics (NASDAQ: SRPT - Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, profitability, valuation and dividends. Profitability This table compares Protagonist Therapeutics and Sarepta
- 2026-10-16 Head to Head Review: Genelux (NASDAQ:GNLX) versus Protagonist Therapeutics (NASDAQ:PTGX) Genelux (NASDAQ: GNLX - Get Free Report) and Protagonist Therapeutics (NASDAQ: PTGX - Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, valuation and institutional ownership. Valuation and Earnings This table compares Genelux and Protagonist
- 2026-10-15 Protagonist Therapeutics (PTGX) Upgraded to Strong Buy: Here''s What You Should Know Protagonist Therapeutics (PTGX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company''s earnings prospects. This might drive the stock higher in the near term.
- 2026-09-24 Protagonist Therapeutics (NASDAQ:PTGX) & MiMedx Group (NASDAQ:MDXG) Head-To-Head Review MiMedx Group (NASDAQ: MDXG - Get Free Report) and Protagonist Therapeutics (NASDAQ: PTGX - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, valuation and analyst recommendations. Institutional and Insider Ownership 79.2% of MiMedx Group
- 2026-09-13 Protagonist Therapeutics (NASDAQ:PTGX) CEO Sells $9,289,446.64 in Stock Protagonist Therapeutics, Inc. (NASDAQ: PTGX - Get Free Report) CEO Dinesh Ph Patel sold 63,548 shares of the company''s stock in a transaction dated Wednesday, September 9th. The stock was sold at an average price of $146.18, for a total transaction of $9,289,446.64. Following the completion of the sale, the chief executive officer directly owned 522,968
- 2026-09-13 Protagonist Therapeutics (NASDAQ:PTGX) CEO Sells $7,902,361.38 in Stock Protagonist Therapeutics, Inc. (NASDAQ: PTGX - Get Free Report) CEO Dinesh Ph Patel sold 54,174 shares of the company''s stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $145.87, for a total transaction of $7,902,361.38. Following the completion of the sale, the chief executive officer directly
- 2026-09-11 Hsbc Holdings PLC Purchases 24,045 Shares of Protagonist Therapeutics, Inc. $PTGX Hsbc Holdings PLC raised its position in Protagonist Therapeutics, Inc. (NASDAQ: PTGX) by 1,260.9% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 25,952 shares of the company''s stock after purchasing an additional 24,045 shares during the quarter. Hsbc Holdings PLC''s holdings
- 2026-09-09 Protagonist Therapeutics, Inc. (PTGX) Presents at Citigroup''s Biopharma Back to School Summit 2026 Transcript Protagonist Therapeutics, Inc. (PTGX) Presents at Citigroup''s Biopharma Back to School Summit 2026 Transcript
- 2026-09-08 Protagonist Therapeutics Announces $300 Million Share Repurchase Program NEWARK, CA / ACCESS Newswire / September 8, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that its Board of Directors has authorized a share repurchase program under which the Company may repurchase up to $300 million of its outstanding common stock. The Company intends to fund the share repurchases from its cash, cash equivalents, and marketable securities, and from royalties and other payments received under the Company''s collaboration arrangements with Takeda related to MIMRYLOTM (rusfertide) and with Johnson & Johnson related to ICOTYDETM (icotrokinra).
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 97.3% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Ebit Margin | -281.0% | 64.3% | -131.6% | -479.3% | -458.9% | |
| Ebitda Margin | -278.2% | 65.0% | -126.1% | -466.6% | -448.8% | |
| Operating Profit Margin | -343.6% | 58.2% | -156.1% | -494.2% | -460.0% | |
| Pretax Profit Margin | -281.0% | 64.3% | -131.6% | -479.3% | -458.9% | |
| Continuous Operations Profit Margin | -282.8% | 63.3% | -131.6% | -479.3% | -458.9% | |
| Net Profit Margin | -282.8% | 63.3% | -131.6% | -479.3% | -458.9% | |
| Bottom Line Profit Margin | -282.8% | 63.3% | -131.6% | -479.3% | -458.9% | |
| Current Ratio | 12.710 | 12.482 | 16.714 | 7.796 | 7.741 | |
| Quick Ratio | 12.710 | 12.482 | 16.714 | 7.796 | 7.741 | |
| Solvency Ratio | -2.335 | 4.006 | -3.556 | -3.837 | -2.575 | |
| Cash Ratio | 2.825 | 2.052 | 8.777 | 4.033 | 2.810 | |
| Price To Earnings Ratio | -42.605 | 8.635 | -16.496 | -4.329 | -12.906 | |
| Price To Earnings Growth Ratio | 0.292 | -0.020 | 0.368 | 0.883 | -0.339 | |
| Forward Price To Earnings Growth Ratio | 0.292 | -0.020 | 0.368 | 0.883 | -0.339 | |
| Price To Earnings Diluted Ratio | -42.605 | 9.125 | -16.496 | -4.329 | -12.906 | |
| Price To Earnings Diluted Growth Ratio | 0.287 | -0.023 | 0.368 | 0.883 | -0.339 | |
| Price To Book Ratio | 9.033 | 3.519 | 3.866 | 2.482 | 5.280 | |
| Price To Sales Ratio | 120.664 | 5.470 | 21.693 | 20.129 | 57.910 | |
| Price To Free Cash Flow Ratio | 99.008 | 13.001 | -18.372 | -4.912 | -14.539 | |
| Price To Operating Cash Flow Ratio | 96.278 | 12.905 | -18.532 | -4.948 | -14.687 | |
| Debt To Assets Ratio | 0.015 | 0.015 | 0.003 | 0.015 | 0.017 | |
| Debt To Equity Ratio | 0.017 | 0.016 | 0.003 | 0.017 | 0.020 | |
| Debt To Capital Ratio | 0.017 | 0.016 | 0.003 | 0.017 | 0.019 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.090 | 1.103 | 1.063 | 1.150 | 1.159 | |
| Working Capital Turnover Ratio | 0.086 | 0.989 | 0.220 | 0.105 | 0.096 | |
| Operating Cash Flow Ratio | 1.269 | 3.885 | -3.301 | -3.468 | -2.451 | |
| Operating Cash Flow Sales Ratio | 1.253 | 0.424 | -1.171 | -4.068 | -3.943 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.972 | 0.993 | 1.009 | 1.007 | 1.010 | |
| Debt Service Coverage Ratio | -56.447 | 545.394 | 0.000 | 0.000 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 25.261 | 361.082 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 5.587 | 16.948 | -61.557 | -29.578 | -18.413 | |
| Capital Expenditure Coverage Ratio | 36.271 | 135.906 | -115.330 | -136.021 | -97.970 | |
| Dividend Paid And Capex Coverage Ratio | 36.271 | 135.906 | -115.330 | -136.021 | -97.970 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -42.446 | 8.110 | -14.754 | -3.330 | -11.944 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 97.3% | ▼-2.7% | ▼-2.1% |
| Ebit Margin | -281.0% | ▼-345.3% | ▼-23.7% |
| Ebitda Margin | -278.2% | ▼-343.2% | ▼-27.3% |
| Operating Profit Margin | -343.6% | ▼-401.8% | ▼-64.5% |
| Pretax Profit Margin | -281.0% | ▼-345.3% | ▼-23.7% |
| Continuous Operations Profit Margin | -282.8% | ▼-346.2% | ▼-25.0% |
| Net Profit Margin | -282.8% | ▼-346.2% | ▼-25.0% |
| Bottom Line Profit Margin | -282.8% | ▼-346.2% | ▼-25.0% |
| Current Ratio | 12.710 | ▲0.228 | ▲1.222 |
| Quick Ratio | 12.710 | ▲0.228 | ▲1.222 |
| Solvency Ratio | -2.335 | ▼-6.341 | ▼-0.676 |
| Cash Ratio | 2.825 | ▲0.774 | ▼-1.274 |
| Price To Earnings Ratio | -42.605 | ▼-51.240 | ▼-29.065 |
| Price To Earnings Growth Ratio | 0.292 | ▲0.313 | ▲0.056 |
| Forward Price To Earnings Growth Ratio | 0.292 | ▲0.313 | ▲0.056 |
| Price To Earnings Diluted Ratio | -42.605 | ▼-51.730 | ▼-29.163 |
| Price To Earnings Diluted Growth Ratio | 0.287 | ▲0.309 | ▲0.052 |
| Price To Book Ratio | 9.033 | ▲5.513 | ▲4.197 |
| Price To Sales Ratio | 120.664 | ▲115.194 | ▲75.491 |
| Price To Free Cash Flow Ratio | 99.008 | ▲86.007 | ▲84.171 |
| Price To Operating Cash Flow Ratio | 96.278 | ▲83.373 | ▲82.075 |
| Debt To Assets Ratio | 0.015 | ▲0.001 | ▲0.003 |
| Debt To Equity Ratio | 0.017 | ▲0.001 | ▲0.002 |
| Debt To Capital Ratio | 0.017 | ▲0.001 | ▲0.002 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.090 | ▼-0.013 | ▼-0.023 |
| Working Capital Turnover Ratio | 0.086 | ▼-0.903 | ▼-0.213 |
| Operating Cash Flow Ratio | 1.269 | ▼-2.616 | ▲2.082 |
| Operating Cash Flow Sales Ratio | 1.253 | ▲0.829 | ▲2.754 |
| Free Cash Flow Operating Cash Flow Ratio | 0.972 | ▼-0.020 | ▼-0.026 |
| Debt Service Coverage Ratio | -56.447 | ▼-601.841 | ▼-154.237 |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Short Term Operating Cash Flow Coverage Ratio | 25.261 | ▼-335.821 | ▼-52.008 |
| Operating Cash Flow Coverage Ratio | 5.587 | ▼-11.361 | ▲22.989 |
| Capital Expenditure Coverage Ratio | 36.271 | ▼-99.635 | ▲71.700 |
| Dividend Paid And Capex Coverage Ratio | 36.271 | ▼-99.635 | ▲71.700 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -42.446 | ▼-50.556 | ▼-29.573 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $5.55B | $2.38B | $1.30B | $535.1M | $1.58B | |
| Enterprise value | $5.43B | $2.29B | $1.12B | $413.0M | $1.47B | |
| EV / Sales | 118.10x | 5.27x | 18.60x | 15.54x | 53.60x | |
| EV / Op. cash flow | 94.23x | 12.44x | -15.89x | -3.82x | -13.60x | |
| EV / Free cash flow | 96.90x | 12.53x | -15.75x | -3.79x | -13.46x | |
| EV / EBITDA | -42.45x | 8.11x | -14.75x | -3.33x | -11.94x | |
| Net debt / EBITDA | 0.92x | -0.31x | 2.45x | 0.98x | 0.96x | |
| Current ratio | 12.71x | 12.48x | 16.71x | 7.80x | 7.74x | |
| Income quality | -0.44x | 0.67x | 0.89x | 0.85x | 0.86x | |
| Graham number | — | $33 | — | — | — | |
| Graham net-net | $8 | $8 | $6 | $4 | $6 | |
| Tax burden | 100.6% | 98.5% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Working capital | $532.1M | $544.2M | $334.3M | $211.9M | $296.7M | |
| Invested capital | $543.8M | $556.9M | $336.5M | $216.5M | $303.5M | |
| Return on assets | -19.4% | 37.0% | -22.1% | -51.4% | -36.1% | |
| Operating ROA | -22.4% | 45.9% | -30.9% | -44.1% | -37.4% | |
| Return on tangible assets | -19.4% | 37.0% | -22.1% | -51.4% | -36.1% | |
| Return on equity | -21.2% | 40.8% | -23.5% | -59.1% | -41.8% | |
| Return on invested capital | -25.2% | 35.7% | -27.7% | -59.9% | -41.1% | |
| Return on capital employed | -25.3% | 36.3% | -27.8% | -60.6% | -41.4% | |
| Earnings yield | -2.3% | 11.6% | -6.1% | -23.8% | -7.9% | |
| Free cash flow yield | 1.0% | 7.7% | -5.4% | -20.4% | -6.9% | |
| Capex / Op. cash flow | 2.8% | 0.7% | -0.9% | -0.7% | -1.0% | |
| Capex / Depreciation | 124.2% | 45.7% | 18.4% | 23.6% | 39.7% | |
| Capex / Sales | 3.5% | 0.3% | 1.0% | 3.0% | 4.0% | |
| SG&A / Sales | 97.5% | 10.0% | 55.8% | 119.4% | 99.4% | |
| R&D / Sales | 346.2% | 31.8% | 200.3% | 474.8% | 460.6% | |
| Stock comp / Sales | 99.9% | 8.6% | 48.8% | 91.0% | 59.9% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 36d | 142d | 63d | 1d | 71d | |
| Days payables outstanding | 1591d | 0d | 0d | 0d | 0d | |
| Operating cycle | 36d | 142d | 63d | 1d | 71d | |
| Cash conversion cycle | -1555d | 142d | 63d | 1d | 71d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years